Fujiwara T, Grimm E A, Mukhopadhyay T, Zhang W W, Owen-Schaub L B, Roth J A
Department of Thoracic and Cardiovascular Surgery, University of Texas M. D. Anderson Cancer Center, Houston 77030.
Cancer Res. 1994 May 1;54(9):2287-91.
Recombinant adenovirus-mediated transfer of the wild-type p53 gene into monolayer cultures or multicellular tumor spheroids of human non-small cell lung cancer cell line H358, which has a homozygous deletion of p53, markedly increased the cellular sensitivity of these cells to the chemotherapeutic drug cisplatin. Treated cells underwent apoptosis with specific DNA fragmentation. Direct injection of the p53-adenovirus construct into H358 tumors s.c. implanted into nu/nu mice, followed by i.p. administration of cisplatin, induced massive apoptotic destruction of the tumors. These results support the clinical application of a regimen combining gene replacement using replication-deficient wild-type p53 adenovirus and DNA-damaging drugs for treatment of human cancer.
将野生型p53基因通过重组腺病毒介导转移至人非小细胞肺癌细胞系H358的单层培养物或多细胞肿瘤球体中,该细胞系p53基因存在纯合缺失,这显著增加了这些细胞对化疗药物顺铂的细胞敏感性。经处理的细胞发生凋亡并伴有特异性DNA片段化。将携带p53基因的腺病毒构建体直接注射到皮下接种于裸鼠的H358肿瘤中,随后腹腔注射顺铂,可诱导肿瘤发生大量凋亡性破坏。这些结果支持将使用复制缺陷型野生型p53腺病毒进行基因替代与DNA损伤药物联合的治疗方案应用于人类癌症治疗的临床应用。